Health Condition 1: L400- Psoriasis vulgaris
Conditions
Interventions
Intervention1: Methotrexate plus Apremilast: Tablet Methotrexate at a dose of 0.4mg/kg/week , along with tablet Apremilast initiated with dose titration starting from 10mg on day 1 and gradually incre
Sponsors
Dr Vinayak Upadhyay
Eligibility
Inclusion criteria
Inclusion criteria: Diagnosed case of moderate to severe plaque psoriasis. Willingness to participate and provide written informed consent Ability to comply with treatment and follow up schedule
Exclusion criteria
Exclusion criteria: Patients below age of 18 years or above age of 60 years. Other forms of psoriasis (guttate, erythrodermic, pustular, palmoplantar) Abnormal laboratory parameters (CBC, LFT, renal function) Pregnancy or lactation History of alcohol abuse Chronic or recurrent infections (including tuberculosis) History of lymphoproliferative disorders Bleeding disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare effectiveness and safety of methotrexate and apremilast combination therapy versus tofacitinib monotherapy in the treatment of moderate to severe plaque psoriasis. To assess effectiveness and safety of methotrexate and apremilast combination therapy in the treatment of moderate to severe plaque psoriasis. To assess effectiveness and safety of tofacitinib monotherapy in the treatment of moderate to severe plaque psoriasis. Timepoint: Week 0 , week 4 , week 8 , week 12 , week 16 | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactDr Vinayak Upadhyay
Baba Raghav Das Medical College
Outcome results
None listed